Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted

Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies:
Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies


Agilent Technologies Inc. (NYSE: A) today announced the company is ranked 101 in Newsweek’s 2023 list of America’s Most Responsible Companies, up 28 places from 2022. It marks Agilent’s fourth

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults


Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV)

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Proteasehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease


Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the

Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare


Humana Inc. (NYSE: HUM) is proud to announce that Bruce D. Broussard, President and Chief Executive Officer, is recognized by Modern Healthcare as one of the 100 Most Influential People in

Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions:
Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions


Agilent Technologies Inc. (NYSE: A) today announced the opening of a new Customer Experience Center (CEC) in Lexington, MA, focused on solutions from Agilent genomics and diagnostics product

Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Dayhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day


Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST

QuidelOrtho to Host Investor Day on December 13, 2022: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Host Investor Day on December 13, 2022


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers


Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile

Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab:
Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab


Agilent Technologies Inc. (NYSE: A) today announced that it has become the first ‘Angel’ level sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of

Agilent Deploys Next Generation Explosive Detection System at London Heathrow Airport:
Agilent Deploys Next Generation Explosive Detection System at London Heathrow Airport


Agilent Technologies Inc. (NYSE: A) today announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler

Agilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results:
Agilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.85 billion for the fourth quarter ended Oct. 31, 2022, an increase of 11% compared to the fourth quarter of 2021 and up 17% on a

Agilent Announces Cash Dividend of 22.5 Cents Per Share:
Agilent Announces Cash Dividend of 22.5 Cents Per Share


Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 22.5 cents per share of common stock, reflecting a 7% increase over the previous quarter. The

Agilent to Present at the Evercore ISI HealthCONx Conference:
Agilent to Present at the Evercore ISI HealthCONx Conference


Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 5th Annual Evercore ISI

Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0:
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0


Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe

Waters Highlights ESG Progress and New Commitments in its 2022 Report: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters Highlights ESG Progress and New Commitments in its 2022 Report


Waters Corporation (NYSE:WAT) today released its 2022 Environmental, Social, and Governance (ESG) Report highlighting the company’s efforts for 2021 and the first half of 2022 to reduce its

CenterWell Senior Primary Care Brings Personalized Primary Care to Louisville, Opening 3 Centers by mid-2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
CenterWell Senior Primary Care Brings Personalized Primary Care to Louisville, Opening 3 Centers by mid-2023


CenterWell Senior Primary Care will open three new senior-focused primary care centers in Louisville through mid-2023, marking the company’s debut in Kentucky and giving local seniors access to

Agilent Joins the How2Recycle Program:
Agilent Joins the How2Recycle Program


Agilent Technologies Inc. (NYSE: A) has become a member of How2Recycle®, a standardized labeling system owned by Delaware nonprofit Green Blue Institute, Inc. The program involves a coalition of

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccinehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myelomahttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma


Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the